Amylin
Amylin (Islet Amyloid Polypeptide, IAPP)
A pancreatic hormone co-secreted with insulin that reduces appetite, slows gastric emptying, and suppresses glucagon. Pramlintide (synthetic amylin) is FDA-approved for diabetes.
Mechanism of Action
Amylin binds to amylin receptors in the area postrema and hypothalamus, reducing appetite and food intake. It also slows gastric emptying and suppresses postprandial glucagon secretion.
Health Claims & Evidence
Reduces appetite and promotes satiety
Improves postprandial glucose control
Supports weight loss in diabetes
Short-Term Effects
Reduced postprandial glucose, decreased appetite, nausea (especially initially).
Long-Term Effects
Sustained glucose control and modest weight loss.
Side Effects
Nausea (most common), hypoglycemia risk when combined with insulin.
Contraindications
Hypoglycemia unawareness. Requires insulin dose adjustment.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Pramlintide and glycemic control in type 1 diabetes
Whitehouse et al. · Diabetes Care · 2002
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Amylin and related peptides, and prepare an educational research summary.
Explore Research